EUVIMEDEUVIMED entdecken
Crossref

Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays

Shu-Ping Chao iD, Wei-Che Lin, Cheng-Hsien Lu, Hsiu-Chuan Wu, Hsing-Cheng Liu, Chaur-Jong Hu iD

Journal of Alzheimer’s Disease · 2024

DOI: 10.3233/jad-240690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Shu-Ping Chao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dementia Center, Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, tau Proteins, Biomarkers. Die Arbeit nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many groups have been using immunomagnetic reduction (IMR) for assaying plasma amyloid-β 1-40 (Aβ 1-40 ) peptide, Aβ 1-42 peptide and total tau protein (T-Tau) in cognitively normal controls (NC), patients with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease dementia (ADD). Tremendous results have been independently reported.

Objective

We used traditional knowledge databases (e.g., PubMed, Embase), papers published at international conferences, and private communications to obtain data involving the use of IMR assay for plasma biomarkers of plasma Aβ 1-40 , Aβ 1-42 , and T-Tau in NC, aMCI, and ADD.

Methods

Results of thirty studies were analyzed, including twenty-five studies published in papers, two studies presented at conferences and three unpublished studies.

Results

Among the thirty studies, there were 1189 subjects of NC, 544 aMCI patients and 853 ADD patients. The average value of plasma Aβ 1-40 in subjects significantly decreased from NC (59.72 pg/ml) to aMCI (45.92 pg/ml, p < 0.0001), which was no significant different from ADD (48.34 pg/ml, p > 0.05). The average level of plasma Aβ 1-42 significantly increased from NC (15.72 pg/ml) to aMCI (17.66 pg/ml, p < 0.0001), which was not significantly different from ADD (19.39 pg/ml, p > 0.05). However, the average level of plasma T-Tau significantly increased from NC (17.92 pg/ml) to aMCI (28.26 pg/ml, p < 0.0001), further significantly increased to AD (35.51 pg/ml, p < 0.001).

Conclusions

Plasma Aβ 1-40 , Aβ 1-42 , and T-Tau levels are able to discriminate NC from patients with aMCI and ADD. Plasma T-Tau levels are disease-severity dependent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-Peptidestau ProteinsBiomarkersPeptide FragmentsCognitive DysfunctionHumansImmunomagnetic SeparationFemaleMaleAged

Stichwörter der Autor:innen

Alzheimer's diseaseAlzheimer's disease dementiaamnestic mild cognitive impairmentamyloidimmunomagnetic reductionplasma biomarkerstau protein

Substanzen

Amyloid beta-Peptidestau ProteinsBiomarkersPeptide Fragmentsamyloid beta-protein (1-42)amyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Dementia Center, Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
  • Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, New Taipei City, Taiwan.
  • Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of General Psychiatry, Taipei City Hospital Songde Branch, Taipei, Taiwan.

ORCID-Profile: Shu-Ping Chao, Chaur-Jong Hu

Zitieren

APA

Chao, S. P., Lin, W. C., Lu, C. H., Wu, H. C., Liu, H. C., & Hu, C. J. (2024). Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240690

Vancouver

Chao SP, Lin WC, Lu CH, Wu HC, Liu HC, Hu CJ. Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240690

BibTeX
@article{Chao2024,
  author = {Chao, Shu-Ping and Lin, Wei-Che and Lu, Cheng-Hsien and Wu, Hsiu-Chuan and Liu, Hsing-Cheng and Hu, Chaur-Jong},
  title = {Changes in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.3233/jad-240690}
}
Kostenlos starten →